Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are female and aged 18 years or older
- People who have given written consent to take part, including agreement for stored tumor tissue samples to be tested
- People who have been newly diagnosed with advanced endometrial cancer (stage III or IV), confirmed by tissue analysis, where the diagnosis was made within the last 4 months before joining the study
- People whose cancer is one of the following types: high-grade endometrioid (G3), serous carcinoma, clear cell carcinoma, mixed carcinoma, undifferentiated or dedifferentiated carcinoma, carcinosarcoma, or certain other similar types
- People for whom a stored tumor tissue sample (taken during a biopsy or surgery) is available
- People whose original medical records and documentation are available for review
Who may not be able to join:
- People who have been taking part in another clinical (interventional) trial since being diagnosed with advanced endometrial cancer
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-877-240-9479
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The rate of POLEm positive status; The rate of dMMR status and pMMR status detected by IHC and by combined approach of molecular classification; The rate of p53abn positive status detected by IHC and by combined approach of molecular classification; The rate of PD-L1 positive status detected by IHC; The rate of HER2 expression 3+ detected by IHC
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.